You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Cillo A, Cardello C, Karapetyan L, et al
818 Combination therapy with anti-PD1 and anti-LAG3 leads to unique peripheral and intratumoral CD8+ T cells signatures in patients with metastatic melanoma
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.0818